title: Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
abstract: Cardiovascular disease (CVD) is prevalent in patients with chronic kidney disease (CKD). In hemodialysis (HD) patients, some protein-bound uremic toxins are considered to be associated with CVD. However, it is not yet known which uremic toxins are important in terms of endothelial toxicity. Serum samples were obtained from 45 HD patients before and after HD. Total and free serum concentrations of indoxyl sulfate, indoxyl glucuronide, indoleacetic acid, p-cresyl sulfate, p-cresyl glucuronide, phenyl sulfate, phenyl glucuronide, phenylacetic acid, phenylacetyl glutamine, hippuric acid, 4-ethylphenyl sulfate, and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) were simultaneously measured by liquid chromatography/electrospray ionization-mass spectrometry/mass spectrometry (LC/ESI-MS/MS). The effects of these solutes at their pre-HD mean and maximum serum concentrations on reactive oxygen species (ROS) production in human umbilical vein endothelial cells (HUVEC) were measured with a ROS probe. Serum levels of 11 of the solutes (all except 4-ethylphenyl sulfate) were significantly increased in HD patients compared to healthy subjects. All 12 solutes showed changes in their protein-binding ratios. In particular, indoxyl sulfate, p-cresyl sulfate, CMPF, and 4-ethylphenyl sulfate showed high protein-binding ratios (>95 %) and low reduction rates by HD (<35 %). Indoxyl sulfate at its mean and maximum pre-HD serum concentrations-even with 4 % albumin-stimulated ROS production in HUVEC most intensely, followed by CMPF. In conclusion, the serum levels of 11 protein-bound uremic toxins were increased in HD patients. Indoxyl sulfate, p-cresyl sulfate, and CMPF could not be removed efficiently by HD due to their high protein-binding ratios. Indoxyl sulfate most intensely induced endothelial ROS production, followed by CMPF.
authors.affiliation: Biomedical Research Laboratories, Kureha Corporation, 3-2-2, Nihonbashi-Hamacho, Tokyo 103-8552, Japan.
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Itoh
authors.forename: Atsuko
authors.initials: A
authors.lastname: Ezawa
authors.forename: Kaori
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Tsuruta
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Niwa
mesh_terms: D000368:Aged; D002478:Cells, Cultured; D002853:Chromatography, Liquid / Q000379:methods*; D004730:Endothelium, Vascular / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000378:metabolism*; D017382:Reactive Oxygen Species / Q000378:metabolism*; D006435:Renal Dialysis; D053719:Tandem Mass Spectrometry / Q000379:methods*; D014118:Toxins, Biological / Q000097:blood*; D014511:Uremia / Q000378:metabolism*
chemical_list: D011506:Proteins; D017382:Reactive Oxygen Species; D014118:Toxins, Biological